公开(公告)号：US20230346804A1

公开(公告)日：2023-11-02

申请号：US18141805

申请日：2023-05-01

申请人： EIRGEN PHARMA LTD

发明人： Eric J. Messner ,  P. Martin Petkovich ,  Jay A. White ,  Samir P. Tabash ,  Joel Z. Melnick ,  Charles W. Bishop

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/48

CPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/4858

摘要： Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxyvitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxyvitamin D.

公开(公告)号：US20190183908A1

公开(公告)日：2019-06-20

申请号：US16099726

申请日：2017-05-15

申请人： Case Western Reserve University

发明人： Kurt Q. Lu

IPC分类号： A61K31/593 ,  A61P29/00 ,  A61P17/02 ,  A61K9/00

CPC分类号： A61K31/593 ,  A61K9/0053 ,  A61K31/00 ,  A61K31/592 ,  A61P17/02 ,  A61P29/00

摘要： An autophagy activator, such as vitamin D, for use in a method of treating or preventing skin damage in a subject in need thereof is described, that includes administering to the subject a therapeutically effective amount of said activator. The method can include administering doses of the autophagy activator that are substantially higher than those typically used. Also disclosed are a method of monitoring the immunomodulatory effects of an autophagy activator on skin damage in a subject, and a method of correlating the dosage of oral administration of cholecalciferol in humans with the dosage of an intraperitoneal injection of 25(OH)D in mice.

公开(公告)号：US20180271884A1

公开(公告)日：2018-09-27

申请号：US15990352

申请日：2018-05-25

申请人： OPKO IRELAND GLOBAL HOLDINGS, LTD.

发明人： Jay A. White ,  Samir P. Tabash ,  Sammy A. Agudoawu ,  Joel Z. Melnick

IPC分类号： A61K31/593 ,  A61K9/48 ,  A61K9/28 ,  A61K9/20 ,  A61K47/38 ,  A61K47/44 ,  A61K31/592

CPC分类号： A61K31/593 ,  A61K9/2054 ,  A61K9/2866 ,  A61K9/4866 ,  A61K31/592 ,  A61K47/38 ,  A61K47/44 ,  A61K2300/00

摘要： A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

公开(公告)号：US20180214577A1

公开(公告)日：2018-08-02

申请号：US15876821

申请日：2018-01-22

申请人： The USA, as represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

发明人： Paul Albert SIEVING ,  Ronald Avery BUSH ,  Peter C. COLOSI ,  Yong ZENG

IPC分类号： A61K48/00 ,  A61P27/02 ,  A61K38/17 ,  A61K9/00 ,  A61K45/06 ,  A61K33/06 ,  A61K31/592 ,  A61K31/593 ,  C12N15/86

CPC分类号： A61K48/0058 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0306 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/592 ,  A61K31/593 ,  A61K33/06 ,  A61K38/1709 ,  A61K45/06 ,  A61P27/02 ,  C07K14/4726 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2830/008 ,  A61K2300/00

摘要： Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.

公开(公告)号：US20180200206A1

公开(公告)日：2018-07-19

申请号：US15744004

申请日：2016-07-14

申请人： ATOSSA GENETICS INC.

发明人： Steven C. Quay

IPC分类号： A61K31/138 ,  A61K9/00 ,  A61K31/202 ,  A61K31/592 ,  A61K31/593 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/138 ,  A61K9/0041 ,  A61K31/202 ,  A61K31/357 ,  A61K31/405 ,  A61K31/592 ,  A61K31/593 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00

摘要： Methods and treatments are taught for the treatment of breast disorders, including proliferative breast disease, breast cancer, and increased breast density. The methods and compositions deliver efficacious formulations of chemical and/or biological treatment medicaments to the breast via a transpapillary route.

公开(公告)号：US20180125901A1

公开(公告)日：2018-05-10

申请号：US15801941

申请日：2017-11-02

申请人： CELL BIOTECH CO., LTD.

发明人： Myung Jun CHUNG

IPC分类号： A61K35/744 ,  A61P3/04 ,  A61K35/747 ,  A61K9/00 ,  A61K31/51 ,  A61K31/525 ,  A61K31/455 ,  A61K31/4415 ,  A61K31/4188 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K31/59

CPC分类号： A61K35/744 ,  A61K9/0053 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/59 ,  A61K31/592 ,  A61K31/593 ,  A61K31/714 ,  A61K35/74 ,  A61K35/747 ,  A61K45/06 ,  A61K2035/11 ,  A61P1/16 ,  A61P3/00 ,  A61P3/02 ,  A61P3/04 ,  A61P3/06 ,  A61P3/08 ,  A61P3/10 ,  A61P9/12 ,  A61P19/08 ,  A61P19/10 ,  A61K2300/00

摘要： The present invention relates to a functional composition for preventing, alleviating or treating bone disease and lipid-related metabolic disease, and more particularly to a composition which comprises a combination of probiotics and a vitamin complex, which is capable of effectively preventing, alleviating or treating bone disease, obesity and lipid-related metabolic disease by synergistic effects on antioxidant activity, a reduction in blood lipid levels and the promotion of in vivo absorption of calcium and iron.

公开(公告)号：US09949992B2

公开(公告)日：2018-04-24

申请号：US14358468

申请日：2012-11-14

申请人： DUKE UNIVERSITY

发明人： Kenneth W. Lyles ,  Cathleen S. Colon-Emeric ,  Christopher M. O'Connor ,  Dennis Abraham ,  Kent Nilsson ,  Howard Rockman ,  Graham Russell

IPC分类号： A61K31/675 ,  A61K45/06 ,  A61K31/663 ,  A61K31/592 ,  A61K31/593 ,  A61K31/662

CPC分类号： A61K31/675 ,  A61K31/592 ,  A61K31/593 ,  A61K31/662 ,  A61K31/663 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analog or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.

公开(公告)号：US20180085381A1

公开(公告)日：2018-03-29

申请号：US15502498

申请日：2015-08-06

申请人： OPKO IRELAND GLOBAL HOLDINGS, LTD.

发明人： P. Martin Petkovich ,  Joel Z. Melnick ,  Jay A. White ,  Samir P. Tabash ,  Charles W. Bishop ,  Susan Peers ,  Stephen A. Strugnell

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K47/06 ,  A61K47/14 ,  A61K47/38 ,  A61K9/00 ,  A61K45/06

CPC分类号： A61K31/593 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4875 ,  A61K31/135 ,  A61K31/137 ,  A61K31/592 ,  A61K31/663 ,  A61K31/675 ,  A61K39/395 ,  A61K45/06 ,  A61K47/06 ,  A61K47/14 ,  A61K47/26 ,  A61K47/38 ,  A61K47/44 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  A61K2300/00

摘要： Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

公开(公告)号：US20180049999A1

公开(公告)日：2018-02-22

申请号：US15561249

申请日：2016-04-06

申请人： Atossa Genetics Inc.

发明人： Steven C. Quay

IPC分类号： A61K31/138 ,  A61K31/565 ,  A61K31/4196 ,  A61K31/202 ,  A61K31/593 ,  A61K31/592

CPC分类号： A61K31/138 ,  A61K9/70 ,  A61K31/202 ,  A61K31/4196 ,  A61K31/53 ,  A61K31/565 ,  A61K31/592 ,  A61K31/593 ,  A61K2300/00 ,  A61P35/00

摘要： The present invention relates to pharmaceutical compositions comprising at least one therapeutic agent, a fatty acid mixture comprising at least one omega-3 fatty acid, and at least one vitamin D compound. Also described are methods of preparation of such compositions, and methods of prevention and treatment of breast disorders and estrogen-related disorders.

公开(公告)号：US09895381B2

公开(公告)日：2018-02-20

申请号：US14959105

申请日：2015-12-04

申请人： Salk Institute for Biological Studies

发明人： Mara Sherman ,  Michael Downes ,  Ronald M. Evans

IPC分类号： A61K31/7068 ,  A61K45/06 ,  A61K31/592 ,  A61K31/593 ,  A61K31/517 ,  A61K31/513 ,  A61K47/62 ,  A61K47/68 ,  A61K9/00 ,  A61K31/424 ,  A61K31/43 ,  A61K31/496

CPC分类号： A61K31/593 ,  A61K9/0019 ,  A61K31/424 ,  A61K31/43 ,  A61K31/496 ,  A61K31/513 ,  A61K31/517 ,  A61K31/592 ,  A61K31/7068 ,  A61K45/06 ,  A61K47/62 ,  A61K47/6849 ,  A61K2300/00

摘要： Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.